Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-30T19:41:36.479Z Has data issue: false hasContentIssue false
  • English
  • Français

COVID-19 Vaccines and Roles of the Health Regulatory Authority in Tunisia

Published online by Cambridge University Press:  28 July 2022

Nour Chtiba Open the ORCID record for Nour Chtiba [Opens in a new window] ,
Dora Cherif ,
Imène Mersni ,
Meriem Kadri ,
Aroua Jemei ,
Imed Lassoued  and
Myriam Razgallah Khrouf
Nour Chtiba*
Affiliation:
Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia
Dora Cherif
Affiliation:
Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia
Imène Mersni
Affiliation:
Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia
Meriem Kadri
Affiliation:
Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia
Aroua Jemei
Affiliation:
Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia
Imed Lassoued
Affiliation:
Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia
Myriam Razgallah Khrouf
Affiliation:
Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia
*
Corresponding author: Nour Chtiba, Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Given the unstoppable spread of coronavirus disease (COVID-19), the development of a vaccine was needed to contain the pandemic. In such a situation of global emergency, regulatory authorities ensured timely, safe, and equitable access to the vaccine.

This article aims to outline the roles of the Tunisian regulatory authority, the Directorate of Pharmacy and Medicines (DPM) at the Ministry of Health, in registration and procurement of the COVID-19 vaccine.

Requirement to grant the Exceptional Provisional Authorizations of Marketing (EPAM) for COVID-19 vaccines was 27 days versus 869 days for conventional marketing authorizations (MAs). The DPM has optimized its activity through: early dialogue with manufacturers, online submission, the use of distance communication technologies. It has demonstrated unprecedented flexibility through the continuous and rolling review approach.

Regulatory authorities in Tunisia and around the world have partnered with manufacturers to speed up administrative procedures while ensuring the quality, safety, and efficacy of vaccines.

Keywords

assessmentCOVID-19exceptional provisional authorizations of marketingfast-track of vaccine registration and procurementhealth regulatory authority
Type
Report from the Field
Information
Disaster Medicine and Public Health Preparedness , Volume 16 , Issue 6 , December 2022 , pp. 2694 - 2696
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Maladie COVID-19 (Nouveau Coronavirus). Institut Pasteur. Published 2020. Accessed June 22, 2021. https://www.pasteur.fr/fr/centre-medical/fiches-maladies/maladie-covid-19-nouveau-coronavirus Google Scholar
Minister of Health. OMNE International Watch Bulletin. Published 2020. https://www.infectiologie.org.tn/pdf_ppt_docs/recommandations/1579896366.pdf Google Scholar
WHO Director-General’s Remarks at the Media Briefing on 2019-nCoV on 11 February 2020. Published 2020. Accessed June 22, 2021. https://www.who.int/director-general/speeches/detail/who-directorgeneral-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 Google Scholar
Order of the Minister of Health of October 15, 2002, Establishing the Composition and Functioning of the Technical Committee of Pharmaceutical Specialties for Marketing Authorization, as Amended by the Order of March 7, 2005 and by the Order of November 24, 2010. http://www.dpm.tn/images/pdf/texte/arrete-15-10-2002.pdf Google Scholar
Article 15 of the Law n°85-91 of November 22, 1985, Regulating the Manufacture and Registration of Medicines Intended for Human Medicine. http://www.dpm.tn/images/pdf/texte/loi-85-91-consolide.pdf Google Scholar
Tunisie: La Banque mondiale débloque 100 millions de dollars pour le 8 déploiement des vaccins COVID-19. World Bank. Published March 30, 2021. Accessed June 22, 2021. https://www.banquemondiale.org/fr/news/press-release/2021/03/30/world-bank-provides-375-million-to-boost-efforts-towards-realizing-the-full-potential-of-pastoralism-in-the-sahel Google Scholar
Rôle et mission de la Direction de la Pharmacie et du medicament. Directorate of Pharmacy and Medicine. Published (n.d.). Accessed June 22, 2021. http://www.dpm.tn/accueil/role-et-mission Google Scholar
FDA Research C for BE and Emergency Use Authorization for Vaccines Explained. FDA. Published 2020. Accessed June 22, 2021. https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency use-authorization- vaccines-explainedGoogle Scholar
Wegner, M. New approaches to regulatory innovation emerging during the crucible of COVID-19. Ther Innov Regul Sci. 2021;55:463-466. https://doi.org/10.1007/s43441-020-00239-8 CrossRefGoogle ScholarPubMed
EMA Initiatives for Acceleration of Development Support and Evaluation Procedures for COVID-19 Treatments and Vaccines. EMA. 2021. https://www.ema.europa.eu/en/documents/other/ema-initiatives-acceleration-development-support-evaluation-procedures-covid-19-treatments-vaccines_en.pdf Google Scholar
Chong, SSF, Kim, M, Limoli, M, et al. Measuring progress of regulatory convergence and cooperation among Asia–Pacific Economic Cooperation (APEC) member economies in the context of the COVID-19 pandemic. Ther Innov Regul Sci. 2021. https://doi.org/10.1007/s43441-021-00285-w Google Scholar